Who is sponsoring NCT03466788?

NCT03466788 is sponsored by Centre Francois Baclesse.

What drugs are being tested in NCT03466788?

Interventions in NCT03466788: Self questionnaires of quality of life and living conditions.

What condition does NCT03466788 study?

NCT03466788 studies Endometrial Cancer, Chemotherapy Effect, Quality of Life.

Is NCT03466788 still recruiting?

NCT03466788 is currently completed. Last updated 18 December 2025.

Are results published for NCT03466788?

Yes — primary outcome results have been posted to ClinicalTrials.gov. See the outcomes section above for details.

Last reviewed 2025-12-18 · How we verify

NCT03466788: EndoQOL

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Impact of Adjuvant Chemotherapy on the Quality of Life of Patients Treated for Stage II / III Endometrial Cancer

Completed NA Results posted Last updated 18 December 2025

What this trial tests

NA trial testing Self questionnaires of quality of life and living conditions in Endometrial Cancer in 51 participants. Completed in 28 March 2020.

Timeline

29 March 2018

Primary endpoint
28 March 2019

28 March 2020

Quick facts

Lead sponsor	Centre Francois Baclesse
Phase	NA
Status	Completed
Study type	INTERVENTIONAL
Allocation	non randomized
Design	parallel
Masking	single
Primary purpose	other
Enrollment	51
Start date	29 March 2018
Primary completion	28 March 2019
Estimated completion	28 March 2020
Sites	5 locations across France

Drugs / interventions tested

Self questionnaires of quality of life and living conditions

Conditions studied

Endometrial Cancer — all drugs for Endometrial Cancer →
Chemotherapy Effect — all drugs for Chemotherapy Effect →
Quality of Life — all drugs for Quality of Life →

Sponsor

Centre Francois Baclesse — full company profile →

Who can join

18 and older, female only, with Endometrial Cancer or Chemotherapy Effect. Patients with the condition only — healthy volunteers not accepted.

Results — posted to ClinicalTrials.gov

Per-arm endpoint measurements with 95% confidence intervals where reported. Source: trial results section.

The Impact in Terms of Overall Quality of Life of Adjuvant Chemotherapy by the QLQ-C30 Questionnaire Primary · 2 years after chemotherapy

The Quality of life questionnaire (QLQ-C30) contains 29 items dealing with fatigue, pain, nausea and vomiting, general condition and social, emotional and cognitive functions. It is currently used in many clinical trials in oncology. Here is the glodal health status scale of the QLQ-C30 questionnaire, ranging from 0 to 100, with high score indicating good quality of life.

Group	Value	95% CI
Patients treated with chemotherapy	61.7	± 13.2
Patients not treated with chemotherapy	71.1	± 18.9

Neurotoxicity Induced by Adjuvant Chemotherapy by the CIPN20 Questionnaire Secondary · 2 years after chemotherapy

The quality of life Questionnaire Chemotherapy Induced Peripheral Neuropathy (QLQ-CIPN20) is a questionnaire specifically dedicated to the evaluation of peripheral neuropathies induced by chemotherapy. This quality of life questionnaire is composed of 20 items from 0 to 4 and has been tested in a large international clinical trial. Here is the sensory scale, ranging from 0 to 100, with high scoring indicating high symptom of neuropathy

Group	Value	95% CI
Patients treated with chemotherapy	20.04	± 18.5
Patients not treated with chemotherapy	6.86	± 11.2

Different Domains of Quality of Life Impacted Remotely by Chemotherapy by the QLQ-C30 Questionnaire Secondary · 2 years after chemotherapy

The Quality of life questionnaire (QLQ-C30) contains 29 items dealing with fatigue, pain, nausea and vomiting, general condition and social, emotional and cognitive functions. QLQ-C30 scoring cinludes 5 functionning scales (physical, role, emotional, cognitive and social), ranging from 0 to 100, with high score indicating high level of quality-of-life. QLQ-C30 scoring includes 9 symptom scales (fatigue, nausea/vomiting, pain, dyspnoea, insomnia, appetite loss, constipation, diarrhea and financial difficulties), ranging from 0 to 100, with high score indicating poor level of quality-of-life.

Physical functioning

Group	Value	95% CI
Patients treated with chemotherapy	75.3	± 19
Patients not treated with chemotherapy	76.8	± 23

Role functioning

Group	Value	95% CI
Patients treated with chemotherapy	77.2	± 24.3
Patients not treated with chemotherapy	80.7	± 27

Emotional functioning

Group	Value	95% CI
Patients treated with chemotherapy	67.1	± 27
Patients not treated with chemotherapy	79.5	± 24.6

Cognitive functioning

Group	Value	95% CI
Patients treated with chemotherapy	76.7	± 21.9
Patients not treated with chemotherapy	81	± 24.3

Social functioning

Group	Value	95% CI
Patients treated with chemotherapy	75.4	± 30.6
Patients not treated with chemotherapy	84.6	± 24.9

Fatigue

Group	Value	95% CI
Patients treated with chemotherapy	38.8	± 23.8
Patients not treated with chemotherapy	22.7	± 17.7

Nausea and vomiting

Group	Value	95% CI
Patients treated with chemotherapy	5.8	± 16.5
Patients not treated with chemotherapy	8.9	± 24.7

Pain

Group	Value	95% CI
Patients treated with chemotherapy	31.6	± 33.7
Patients not treated with chemotherapy	25	± 25.5

Anxiety by the HADS Questionnaire Secondary · 2 years after chemotherapy

The Hospital Anxiety and Depression Scale (HADS) It is a quick and easy self-questionnaire that assesses both anxious and depressive dimensions (7 items for each dimension). Here is the scale of Anxiety, ranging from 0 to 21, with high score reflecting high level of anxiety.

Group	Value	95% CI
Patients treated with chemotherapy	9.7	± 5.3
Patients not treated with chemotherapy	7.7	± 4.9

Depression by the HADS Questionnaire Secondary · 2 years after chemotherapy

The Hospital Anxiety and Depression Scale (HADS) It is a quick and easy self-questionnaire that assesses both anxious and depressive dimensions (7 items for each dimension). Here is the depression scale, ranging from 0 to 21, with high score indicating high level of depression.

Group	Value	95% CI
Patients treated with chemotherapy	5.8	± 4.2
Patients not treated with chemotherapy	4.9	± 3.5

Adverse events — posted to ClinicalTrials.gov

Time frame: 2 years, assessed retrospectively. Patients were included 2 years after their treatment.. Reporting threshold: 0%. Adverse-event reports describe events observed during the trial — not all are caused by the drug.

Patients Treated With Chemotherapy

Serious: 0/20 (0%)

Deaths: 0/20

Patients Not Treated With Chemotherapy

Serious: 0/30 (0%)

Deaths: 0/30

Other adverse events (30 terms — click to expand)

Reaction	System	Patients Treated With Chem…	Patients Not Treated With …
DIARRHOEA	GASTROINTESTINAL DISORDERS	—	—
NAUSEA	GASTROINTESTINAL DISORDERS	—	—
CYSTITIS	INFECTIONS AND INFESTATIONS	—	—
URINARY INCONTINENCE	RENAL AND URINARY DISORDERS	—	—
NEUROPATHY PERIPHERAL	NERVOUS SYSTEM DISORDERS	—	—
ASTHENIA	GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS	—	—
LYMPHOEDEMA	VASCULAR DISORDERS	—	—
POLLAKIURIA	RENAL AND URINARY DISORDERS	—	—
ABDOMINAL PAIN	GASTROINTESTINAL DISORDERS	—	—
DYSPAREUNIA	REPRODUCTIVE SYSTEM AND BREAST DISORDERS	—	—
ANAEMIA	BLOOD AND LYMPHATIC SYSTEM DISORDERS	—	—
VOMITING	GASTROINTESTINAL DISORDERS	—	—
DYSPNOEA	RESPIRATORY, THORACIC AND MEDIASTINAL DISORDERS	—	—
RADIATION SKIN INJURY	INJURY, POISONING AND PROCEDURAL COMPLICATIONS	—	—
PLEURAL EFFUSION	RESPIRATORY, THORACIC AND MEDIASTINAL DISORDERS	—	—
INTERMENSTRUAL BLEEDING	REPRODUCTIVE SYSTEM AND BREAST DISORDERS	—	—
VAGINAL INFECTION	INFECTIONS AND INFESTATIONS	—	—
PAIN	GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS	—	—
RENAL FAILURE	RENAL AND URINARY DISORDERS	—	—
RADIATION PROCTITIS	INJURY, POISONING AND PROCEDURAL COMPLICATIONS	—	—
FEBRILE BONE MARROW APLASIA	BLOOD AND LYMPHATIC SYSTEM DISORDERS	—	—
FATIGUE	GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS	—	—
DEPRESSION	PSYCHIATRIC DISORDERS	—	—
ARTHRALGIA	MUSCULOSKELETAL AND CONNECTIVE TISSUE DISORDERS	—	—
THROMBOCYTOPENIA	BLOOD AND LYMPHATIC SYSTEM DISORDERS	—	—
PROCTITIS	GASTROINTESTINAL DISORDERS	—	—
URINARY TRACT INFECTION	INFECTIONS AND INFESTATIONS	—	—
PELVIC PAIN	REPRODUCTIVE SYSTEM AND BREAST DISORDERS	—	—
ANAL INFLAMMATION	GASTROINTESTINAL DISORDERS	—	—
HAEMORRHOIDS	GASTROINTESTINAL DISORDERS	—	—

Data from ClinicalTrials.gov NCT03466788 adverse events section.

Sponsor's own description

Through this study, The investigator believe to evaluate the impact in terms of overall quality of life of adjuvant chemotherapy in patients with locally advanced endometrial cancer at a distance from their care

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other recruiting trials for Endometrial Cancer

Currently open trials in the same condition.

NCT07419841 — A Phase 1 Study of the Safety and Tolerability of CTX-10726 · Phase 1 · recruiting
NCT07382583 — Development of a Shared Decision Tool to Facilitate Uptake of the Levonorgestrel-releasing Intrauterine System for the P · recruiting
NCT07377734 — Intrauterine Injection of Type III Collage in FST of EC/AEH · Phase 2 · recruiting
NCT07319429 — Refining Fertility-sparing Treatment in Endometrial Carcinoma Based on Molecular Classification · Phase 2, PHASE3 · recruiting
NCT07397624 — Endoscopic Suture Gastroplasty (ESG) for Treatment of Obese Patients With Endometrial Cancer · recruiting

Other Centre Francois Baclesse trials

Trials by the same sponsor.

NCT06959810 — Impact of Adapted Aesthetic Onco in Patients With Upper Aerodigestive Tract Cancer During Their Management · NA · recruiting
NCT06792721 — MEASUREMENT OF CIRCULATING MUTATION BURDEN · recruiting
NCT06817161 — Benefit of Transcutaneous Auricular Vagus Nerve Stimulation in Improving Quality of Life in First Line Treatment of Ovar · Phase 3 · recruiting
NCT06612827 — Development of Tumor Organoids From Undifferentiated Primary Carcinomas to Guide Therapeutic Decisions · recruiting
NCT06798922 — Flap Sparing in Postoperative Radiotherapy of Oral Cavity Cancers · Phase 3 · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03466788 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Centre Francois Baclesse
Last refreshed: 18 December 2025

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03466788.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing